Canadian company (DDS) may revolutionize the antidepressant drug market
As I look over the destruction in the small cap biotech arena recently, I cannot help but come to the conclusion that these two small cap biotech stocks are undervalued. Both stocks are way off their highs when great drug news was recently revealed. Each has pulled back by close to, if not more than 50% from those highs.
Labopharm Inc. (TSX: T.DDS, Stock Forum) is the first I wish to highlight. This stock had great news about a week ago when they got FDA approval for their drug OLEPTRO. This drug is an extended release tablet, once-daily formulation of the antidepressant Trazodone.
To continue reading please click here
Copyright 2010 Stockhouse
